Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

MSMB Capital Derails Acquisition of $ALTH by $AMAG

Martin Shkreli, MSMB Capital has succeeded in derailing the acquisition of Allos Therapeutics Inc. (ALTH) by AMAG Pharmaceuticals Inc. (AMAG). According to Bloomberg, AMAG announced today that “it didn’t get enough investor votes to support its $184.8 million acquisition of ALTH.”

Phill Gross

Martin Shkreli Led Shareholder Opposition

Martin Shkreli was so strongly against the deal that he took a 5.8% ownership interest in AMAG to try to prevent it. He went so far as to actively push against it through his position on the board. At one point, Shkreli even pushed to have several members of AMAg’s board dismissed and replaced with people from MSMB. While Shkreli was the most adamant that the deal between ALTH and AMAG not go through, he was far from alone in his opposition. Adage Capital Management and Palo Alto Investors, which own 17.5% and 15% of AMAG respectively, have both publicly said they were opposed to any merger or acquisition between AMAG and ALTH, explaining that they do not see the rationale behind the deal, strategically nor financially. Martin Shkreli’s push against the merger left a sour taste in the mouth of at least one board member, who was quoted by TheStreet as saying, “Voting no on the Allos deal is a referendum against Amag’s management team.”

AMAG and ALTH’s Fate Going Forward

The failed merger also affected the market. Once the collapse of the deal was announced, ALTH fell to a historic low. When AMAG first began talks with ALTH, its share price was around $2.44. ALTH closed yesterday at just $1.75 a share. Bloomberg reports, “Allos dropped 4.8 percent to $1.39 at 10:54 a.m., after earlier declining to $1.28, the shares’ lowest value since their initial public offering in March 2000. Through yesterday, they were down 68 percent this year.AMAG rose 1 cent to $13.65. The shares had fallen 25 percent this year before today.” According to Bloomberg, Shkreli remains motivated – “MSMB, which owned 5.9 percent of AMAG as of Oct. 7, had made an unsolicited bid to buy the company in August for $18 a share, or $378 million. Martin Shkreli, MSMB’s chief investment officer, said today his plans still stand.”

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!